Nils Wilking

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: MOLECULAR ONCOLOGY. 2023;17(6):925-945
Engaging European society at the forefront of cancer research and care How discussions at the 5^th Gago Conference on European Science policy led to the Heidelberg Manifesto
Baumann M; Celis J; Ringborg U; Heitor M; Berns A; Albreht T; Arabadjiev J; Boutros M; Brandenburg M; Canhao H; Carneiro F; Chomienne C; De Lorenzo F; Eggermont AMM; Font A; Garralda E; Goulart M; Henrique R; Lawler M; Maier-Hein L; Meunier F; Oberst S; Oliveira P; Papatriantafyllou M; Schuez J; Solary E; Valencia A; Vargas R; Weiderpass E; Wilking N
Article: JOURNAL OF CANCER POLICY. 2022;34:100362
Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe
Hofmarcher T; Lindgren P; Wilking N
Article: NATURE REVIEWS CLINICAL ONCOLOGY. 2022;19(3):207-215
The value of anticancer drugs - a regulatory view
Pignatti F; Wilking U; Postmus D; Wilking N; Delgado J; Bergh J
Article: MOLECULAR ONCOLOGY. 2021;15(10):2507-2543
The Porto European Cancer Research Summit 2021
Ringborg U; Berns A; Celis JE; Heitor M; Tabernero J; Schuz J; Baumann M; Henrique R; Aapro M; Basu P; Beets-Tan R; Besse B; Cardoso F; Carneiro F; van den Eede G; Eggermont A; Froehling S; Galbraith S; Garralda E; Hanahan D; Hofmarcher T; Joensson B; Kallioniemi O; Kasler M; Kondorosi E; Korbel J; Lacombe D; Machado JC; Martin-Moreno JM; Meunier F; Nagy P; Nuciforo P; Oberst S; Oliveiera J; Papatriantafyllou M; Ricciardi W; Roediger A; Ryll B; Schilsky R; Scocca G; Seruca R; Soares M; Steindorf K; Valentini V; Voest E; Weiderpass E; Wilking N; Wren A; Zitvogel L
Article: JOURNAL OF CANCER POLICY. 2021;28:100279
Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets
Rachev B; Wilking N; Kobelt G; Spandonaro F; Rajer M; Roediger A; Normand R; Zielinski C
Article: EUROPEAN JOURNAL OF CANCER. 2020;129:41-49
The cost of cancer in Europe 2018
Hofmarcher T; Lindgren P; Wilking N; Jonsson B
Article: EUROPEAN JOURNAL OF CANCER. 2016;66:162-170
The cost and burden of cancer in the European Union 1995-2014
Jonsson B; Hofmarcher T; Lindgren P; Wilking N
Article: EUROPEAN JOURNAL OF CANCER CARE. 2015;24(1):99-110
Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey
Vrdoljak E; Torday L; Sella A; Leyman S; Bavbek S; Kharkevich G; Mardiak J; Szczylik C; Znaor A; Wilking N
Article: ACTA ONCOLOGICA. 2014;53(9):1197-1204
Audio-recorded information to patients considering participation in cancer clinical trials - a randomized study
Bergenmar M; Johansson H; Wilking N; Hatschek T; Brandberg Y
Article: CHINESE CLINICAL ONCOLOGY. 2014;3(2):23
The positioning of economic principles under the changing conditions of the novel drug developmental process in cancer.
Wilking N; Wilking U; Jönsson B
Article: BREAST. 2013;22(6):1142-1147
Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel
Linderholm BK; Lidbrink E; Tallroth E; Einbeigi Z; Svensson H; von Wachenfeldt A; Norberg B; Carlsson L; Olsson ME; Bergh J; Wilking N; Hatschek T
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(1):52-59
Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial
Fahlen M; Fornander T; Johansson H; Johansson U; Rutqvist L-E; Wilking N; von Schoultz E
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2012;8(9):1360-1363
Cancer vaccines and immunotherapeutics Challenges for pricing, reimbursement and market access
Jonsson B; Wilking N
Article: LAKARTIDNINGEN. 2010;107(40):2376-2377
[Great risk of future problems for Swedish cancer care].
Bergh J; Wilking N
Article: LAKARTIDNINGEN. 2010;107(16):1064
[Towards targeted treatment].
Wilking N
Article: EJHP PRACTICE. 2009;15(4):18-19
Access to cancer care is a key factor to progress in cancer treatment outcome
Jonsson B; Wilking N
Article: THORAX. 2008;63(10):866-871
Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway:: a national study
von Plessen C; Strand T-E; Wentzel-Larsen T; Omenaas E; Wilking N; Sundstrom S; Sorenson S
Article: ANNALS OF ONCOLOGY. 2007;18:67-77
The effect of cancer drug vintage on cancer survival and mortality
Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:55-66
Market access for cancer drugs and the role of health economics
Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:49-54
Cancer research and development and the drug development process
Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:31-48
Market uptake of new oncology drugs
Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:23-30
Medical review
Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:8-22
The burden and cost of cancer
Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:1
A global comparison regarding patient access to cancer drugs -: Preface
Jonsson B; Wilking N
Article: TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING. 2006;126(21):2828-2829
[Do Norwegian cancer patients receive the care they deserve?].
Wilking N; Jönsson B; Svedman C
Article: CLINICAL CANCER RESEARCH. 2006;12(14):4185-4191
Basoluminal carcinoma:: A new biologically and prognostically distinct entity between basal and luminal breast cancer
Laakso M; Tanner M; Nilsson J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmstroem P; Wilking N; Bergh J; Isola J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2006;24(16):2428-2436
Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmstrom P; Wilking N; Nilsson J; Bergh J
Article: EUROPEAN JOURNAL OF CANCER. 2000;36(8):976-982
High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment
Kvinnsland S; Anker G; Dirix LY; Bonneterre J; Prove AM; Wilking N; Lobelle JP; Mariani O; di Salle E; Polli A; Massimini G
Article: JOURNAL OF CLINICAL ONCOLOGY. 1999;17(5):1413-1424
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
Nabholtz JM; Senn HJ; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Molino A; Nortier JWR; Richel DJ; Nagykalnai T; Siedlecki P; Wilking N; Genot JY; Hupperets PSGJ; Pannuti F; Skarlos D; Tomiak EM; Murawsky M; Alakl M; Riva A; Aapro M
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(10):1536-1545
Gastrointestinal tract cancer liaison office: an attempt to organise clinical research in Europe
Bleiberg H; Gerard B; Wils J; Blijham G; DiazRubio E; Herrmann R; Kerr D; Labianca R; Rougier P; Wilke HJ; Wilking N
Article: NEW ENGLAND JOURNAL OF MEDICINE. 1997;336(14):980-987
Improved survival with preoperative radiotherapy in resectable rectal cancer
Pahlman L; Glimelius B; Cedermark B; Lundell G; Rubio C; Rutqvist LE; Wilking N; Ost A; Brismar B; Ewerth S; Forsgren L; Johansson C; Magnusson I; Sundelin P; Svensson C; Tornberg B; Theve T; Fenyo G; Svensson SO; Goldman S; Molin K; Bark S; Sundblad M; Dalen J; Lindholmer C; Robertsson B; Ohman U; Nilsson SE; Dahlberg M; Graf W; JanssonFrykholm G; Lindmark G; Westman M; Liljeholm H; Bendtsen O; Ljungquist U; Nihlberg A; Heuman R; Lorentz T; BisgaardPedersen A; Bergstrom S; Krog M; Tuvesson T; Edman P; Lindstrom C; Sandhammar B; Tyden G; Bergman L; Enander LK; Underskog I; Sellstrom H; Armatys P; Moell P; Hellberg R; Stenstam B; Dafnis G; Hojer H; Baldetorp L; Hatschek T; Sjodahl R; Arbman G; Nilsson E; StorgrenFordell V; Hugander A; Lagerberg F; Simert G; delaRue RA; Aldman A; Lannerstad O; Gullstrand P; Arwidi A; Bohe M; Ekelund G; Jiborn H; Landberg T; Graffman S; Jansson O; Jeppson B; Sorbris R; Ohlsson E; Lenninger S; Hallden K; Norryd C; Adamsen S; Hultborn R; Nilsson S; Magnusson O; Soderberg HE; Lindberg B; Tveit E; Jansson R; Svensson JH; Gustafsson A; Almskog B; Salander H; Holmlund D; Filipsson S; Laino R; Athlin L; Bengtsson NO; Groman G; Lundegard G; Dedorson S; Henriksson G; Nordahl A; Ryd G; Edlund G; Svensson JO; Rutegard J; Fagerberg M; Edin K
Article: BRITISH JOURNAL OF CANCER. 1996;74(3):479-481
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor
Smith I; Jones A; Spielmann M; Namer M; Green MD; Bonneterre J; Wander HE; Hatschek T; Wilking N; Zalcberg J; Spiers J; Seymour L
Article: BRITISH JOURNAL OF SURGERY. 1996;162(5):397-402
Local recurrence rate in a randomised multicentre trial of preoperative radiotherapy compared with operation alone in resectable rectal carcinoma. Swedish Rectal Cancer Trial.
Article: LAKARTIDNINGEN. 1995;92(9):849-853
[High-dose chemotherapy in breast cancer. Promising results in combination with stem cell support].
Ljungman P; Björkstrand B; Gahrton G; Nordenström J; Shanwell A; Glas U; Rotstein S; Rutqvist LE; Wilking N
Article: ONCOLOGY REPORTS. 1995;2(2):303-306
DIFFERENTIAL-EFFECTS OF FIBROBLAST COCULTURE ON MCF-7 AND MDA-231 BREAST-CARCINOMA CELL INVASION THROUGH MATRIGEL
POPOWICZ P; ENGEL G; WILKING N; LINDER S
Article: JOURNAL OF CLINICAL ONCOLOGY. 1995;13(2):430-434
INFLUENCE OF PRIOR AND SUBSEQUENT PREGNANCY ON BREAST-CANCER PROGNOSIS
VONSCHOULTZ E; JOHANSSON H; WILKING N; RUTQVIST LE
Article: LAKARTIDNINGEN. 1995;92(4):269-275
[The first breast cancer gene isolated. Safer risk assessment for affected families].
Iselius L; Larsson C; Lindblom A; Sandelin K; Wickman M; Wilking N
Visa fler

Alla övriga publikationer

Review: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2023;21(4):537-546
Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe
Henshall CH; Danko D; Barham L; Espin J; Felix J; Harney M; Indra P; Mestre-Ferrandiz J; de Pouvourville G; Spandonaro F; Voncina L; Wilking N
Review: JOURNAL OF CANCER POLICY. 2021;28:100282
The European Code of Cancer Practice.
Lawler M; Oliver K; Gijssels S; Aapro M; Abolina A; Albreht T; Erdem S; Geissler J; Jassem J; Karjalainen S; La Vecchia C; Lievens Y; Meunier F; Morrissey M; Naredi P; Oberst S; Poortmans P; Price R; Sullivan R; Velikova G; Vrdoljak E; Wilking N; Yared W; Selby P
Review: BREAST. 2020;52:78-87
A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments
Cardoso F; Wilking N; Bernardini R; Biganzoli L; Espin J; Miikkulainen K; Schuurman S; Spence D; Spitz S; Ujupan S; Zernik N; Gordon J
Review: ESMO OPEN. 2019;4(6):e000550
Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
Review: ESMO OPEN. 2016;1(6):e000127
The European Cancer Patient's Bill of Rights, update and implementation 2016.
Lawler M; Banks I; Law K; Albreht T; Armand J-P; Barbacid M; Barzach M; Bergh J; Cameron D; Conte P; de Braud F; de Gramont A; De Lorenzo F; Diehl V; Diler S; Erdem S; Geissler J; Gore-Booth J; Henning G; Højgaard L; Horgan D; Jassem J; Johnson P; Kaasa S; Kapitein P; Karjalainen S; Kelly J; Kienesberger A; La Vecchia C; Lacombe D; Lindahl T; Löwenberg B; Luzzatto L; Malby R; Mastris K; Meunier F; Murphy M; Naredi P; Nurse P; Oliver K; Pearce J; Pelouchov J; Piccart M; Pinedo B; Spurrier-Bernard G; Sullivan R; Tabernero J; Van de Velde C; van Herk B; Vedsted P; Waldmann A; Weller D; Wilking N; Wilson R; Yared W; Zielinski C; Zur Hausen H; Le Chevalier T; Johnston P; Selby P
Review: SUPPORTIVE CARE IN CANCER. 2013;21(10):2925-2932
Clinical experience with ZarzioA® in Europe: what have we learned?
Gascon P; Tesch H; Verpoort K; Rosati MS; Salesi N; Agrawal S; Wilking N; Barker H; Muenzberg M; Turner M
Review: ONCOLOGIST. 2013;18(3):248-256
A Review of Breast Cancer Care and Outcomes in Latin America
Justo N; Wilking N; Jonsson B; Luciani S; Cazap E
Review: LAKARTIDNINGEN. 2010;107(16):1075-1080
[Utilization of antineoplastic agents in Sweden and Europe].
Wilking N; Jönsson B; Björn W
Review: ANNALS OF ONCOLOGY. 2009;20(3):403-412
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
McCabe C; Bergmann L; Bosanquet N; Ellis M; Enzmann H; von Euler M; Jonsson B; Kallen K-J; Newling D; Nuessler V; Paschen B; de Wilde R; Wilking N; Teale C; Zwierzina H
Letter: ANNALS OF ONCOLOGY. 2007;18(9):1585-1587
Reply to 'Not credible:: a subversion of science by the pharmaceutical industry.: Commentary on A global comparison regarding patient access to cancer drugs
Jonsson B; Lichtenberg F; Wilking N
Editorial comment: ANNALS OF ONCOLOGY. 2007;18:2-7
A global comparison regarding patient access to cancer drugs -: Summary
Jonsson B; Wilking N
Letter: ACTA ONCOLOGICA. 1998;37(5):495-496
Treatment of rectal cancer.
Wilking N
Published conference paper: ANNALS OF SURGICAL ONCOLOGY. 1996;3(5):423-430
Randomized study on preoperative radiotherapy in rectal carcinoma
Cedermark B; Johansson H; Rutqvist LE; Wilking N; Broberg M; Johansson C; Goldman S; Akerud L; Brismar B; Ewerth S; Lundell G; Rubio C; Singnomklao T; Ost A; Svensson SO; Fenyo G; Eriksson L; Hellstrom B; Lindholmer C; Theve T; Dalen J; Magnusson I; Rieger A; Svensson C; Ohman U; Bark S; Sundblad M

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI